Dr Wouter Zandee provides his thoughts on the symptomatic control of functioning pancreatic NET

Video Transcript

My name is Wouter Zandee, I am an Endocrinologist at the University Medical Center Groningen.

And today I will be discussing how to reduce hormone symptoms from functioning pancreatic neuroendocrine tumours (NETs).

These functioning pancreatic NETs are rare but require specific treatment to reduce the symptoms of hypersecretion to increase quality of life.

Symptom Control

Also, symptom control is required to safely perform surgery or to treat with systemic therapy.

In general, two options exist for reduction of symptoms.

First of all reduction of tumour burden can be considered in accordance with the ENETS guidelines. This can be done with surgery, either curative or with debulking surgery or PRRT with Lu177-DOTATATE, and liver directed therapies can be effective.

Specifically, for hormone secretion several options are also available which I would like to discuss in more detail.

First line therapy is generally a somatostatin analogue (SSA) because of low toxicity and proven decreases in hormone secretion.

SSAs can also decrease glucagon secretion, which increases hypoglycemia in small numbers of patients with an insulinoma. So, for patients with an insulinoma the first administration is done clinically.

If an SSA is ineffective in controlling the hormone symptoms, PRRT with Lu177-DOTATATE is especially effective for patients with functioning pNETs. It has a symptomatic response rate of 71% and increases the quality of life for these patients.

Also everolimus can decrease hypoglycemia in patients with an insulinoma.

In case series sunitinib has been prescribed to decrease diarrhoea for patients with a VIPoma. So, these drugs can also be effective for these patients.

Conclusion

In conclusion, adequate control of symptoms is essential for patients with a functioning pNET to increase quality of life.

Generally, SSAs are first line therapy but if these prove ineffective PRRT can be especially effective in these patients.

Thank you for watching on behalf of NET CONNECT.

Dr Wouter Zandee graduated from medical school in 2010 at the Leiden University with a thesis on the surgical treatment of medullary thyroid carcinoma. Thereafter he started his training to become an internist-endocrinologist. He is currently a fellow in endocrinology at the Erasmus Medical Center, Rotterdam, focusing on several types of endocrine tumors. In the neuroendocrine tumor department he is a sub-investigator of multicenter trials. Concurrently he is pursuing a PhD on neuroendocrine tumors, focusing on biomarkers, treatment of hormonal syndromes (mainly with 177Lu-DOTATATE) and quality of care.

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Ipsen
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
NET CONNECT

NET CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Ipsen and from Eisai Europe Limited.

Meet the experts

Other programmes of interest

video Video
Oncology 
ER+ metastatic breast cancer: Elacestrant and beyond

Follow a patient's journey during and post-elacestrant treatment for ER+/HER2- metastatic breast cancer

Experts
Prof. Maria Vittoria Dieci
Endorsed by
GRASP
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Feb 2024

Educational programme supported by an independent medical education grant from Menarini Stemline Oncology.
podcast Podcast

Episode

3

of 3

episode
Oncology 
Ovarian Cancer: Pre-analytical phase challenges and biomarker testing

Experts
Assoc. Prof. Martina Murphy, Assoc. Prof. Caterina Marchiò, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 32 MIN
  • calendar Feb 2024

Educational programme supported by an independent medical education grant from AstraZeneca and Amoy Diagnostics.
micro-learning Micro learning

Module

2

of 2

module
Oncology 
PARP inhibitors in prostate cancer and the rationale behind combination treatment

Module 2 - Evolving landscape of PARPi in mCRPC: Combination with anti-androgens

Experts
Assoc. Prof. Alicia Morgans, Dr Pasquale Rescigno
Endorsed by
ZERO EAUN
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Jan 2024

Educational programme supported by an independent medical education grant from AstraZeneca
micro-learning Micro learning

Module

1

of 2

module
Oncology 
PARP inhibitors in prostate cancer and the rationale behind combination treatment

Module 1 - PARP inhibitors in advanced prostate cancer

Experts
Assoc. Prof. Alicia Morgans, Dr Pasquale Rescigno
Endorsed by
ZERO EAUN
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Jan 2024

Educational programme supported by an independent medical education grant from AstraZeneca
interactive-patient-case Interactive patient case

Episode

2

of 2

episode
Oncology 
Advanced HCC: Treatment options for patients ineligible for IO

Explore treatment options, adverse event management and next steps in this interactive patient case

Experts
Prof. Sammy Saab
Endorsed by
Blue Faery Digestive Cancers Europe 5th anniversary
Global Liver Institute
  • clock 15 MIN
  • calendar Jan 2024

Educational programme supported by an independent medical education grant from Bayer.
podcast Podcast

Episode

2

of 3

episode
Oncology 
Lung Cancer: Pre-analytical phase challenges and biomarker testing

Moderated by the Oncology Brothers. Episode 2 of a 3-part video podcast series

Experts
Dr Bruna Pellini, Dr Semir Vranić, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Jan 2024

Educational programme supported by an independent medical education grant from AstraZeneca and Amoy Diagnostics.